Identification | Back Directory | [Name]
3-((3S,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile | [CAS]
1092578-48-7 | [Synonyms]
Tofacitinib-16 (3S,4R)-Tofacitinib Tofacitinib Impurity FD+DX YYMGYZDHOQYMFO-DGCLKSJQSA-N Tofacitinib Impurity B(3S,4R) Tofacitinib Impurity B (3S,4R)-Tofacitinib (3S,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile (3S,4R)-4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-beta-oxo-1-piperidinepropanenitrile 1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-, (3S,4R)- 3-((3S,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile Tofacitinib impurity 12/(3S,4R)-Tofacitinib/3-((3S,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile | [Molecular Formula]
C16H20N6O | [MDL Number]
MFCD23105686 | [MOL File]
1092578-48-7.mol | [Molecular Weight]
312.37 |
Chemical Properties | Back Directory | [density ]
1.296 | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | [form ]
Powder | [pka]
6.04±0.60(Predicted) | [InChI]
InChI=1/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13-/s3 | [InChIKey]
UJLAWZDWDVHWOW-PZILLZCRNA-N | [SMILES]
C(#N)CC(N1CC[C@@H](C)[C@H](N(C)C2=NC=NC3NC=CC=32)C1)=O |&1:7,9,r| |
Hazard Information | Back Directory | [Uses]
(3S,4R)-Tofacitinib is an enantiopure stereoisomer of the drug, Janus kinase 3(Jak3) inhibitor (CP-690,550) that has been found to inhibit selected members of the STE7 and STE20 subfamily of kinases. | [storage]
Store at -20°C |
|
|